Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179690 | 0.90 | CA1 (0.60) | KMT2APOLBALDH1A1MEN1KDM4E | |
| SCHEMBL128855 | 0.85 | KMT2A (0.52) | KMT2APOLBALDH1A1MEN1KDM4E | |
| SCHEMBL6382633 | 0.82 | CA1 (0.69) | KMT2APOLBMEN1L3MBTL1CA1 | |
| SCHEMBL17212230 | 0.81 | CA1 (0.60) | KMT2APOLBALDH1A1MEN1CA1 | |
| SCHEMBL129848 | 0.80 | KMT2A (0.50) | KMT2APOLBALDH1A1MEN1KDM4E | |
| SCHEMBL4075703 | 0.79 | SMN1; SMN2 (0.55) | KMT2APOLBALDH1A1MEN1KDM4E | |
| SCHEMBL6555821 | 0.78 | MTNR1B (0.64) | KMT2AALDH1A1MEN1KDM4EGAA | |
| SCHEMBL6380565 | 0.76 | KMT2A (0.62) | KMT2APOLBALDH1A1MEN1L3MBTL1 | |
| SCHEMBL3546981 | 0.76 | MAPT (0.72) | KMT2APOLBALDH1A1MEN1KDM4E | |
| SCHEMBL4083314 | 0.75 | KDM4E (0.53) | KMT2APOLBALDH1A1MEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227966-B2 | Antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140315939-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-10-23 | — | — | US | disclosed |
| US-20120059026-A1 | ANTIMICROBIAL AGENTS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059026-A1 | ANTIMICROBIAL AGENTS | ZYX, Q6ZSR9, ZC3HAV1L | KMT2A 2296/4885POLB 2698/4885ALDH1A1 2930/4885 |
| US-20140315939-A1 | ANTIMICROBIAL AGENTS | ZYX, Q6ZSR9, ZC3HAV1L | KMT2A 2237/4885POLB 3196/4885ALDH1A1 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.